Business Monitor International


Central America Pharmaceuticals & Healthcare Report

Published 28 April 2014

  • 67 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Central America Pharmaceuticals & Healthcare Report

BMI View: Panama and Costa Rica will continue to outperform in compar ison with other Central American countries, namely El Salvador, Guatemala, Honduras, Nicaragua and Belize . I mproving healthcare investment present revenue-generating opportunities for multinational pharmaceutical companies. Generic drugmakers can also benefit from the widespread uptake of generic drugs in the region and its efficient purchasing platforms, such as COMISCA .

Headline Expenditure Projections

  • Pharmaceuticals: US$3.7bn in 2013 to US$3.9bn in 2014; +4.7%. Our forecast has been revised slightly up since Q214 due to more promising industry data.

  • Healthcare: US$16.6bn in 2013 to US$17.5bn in 2014; +5.4 %. Our forecast has been revised downwards since Q214 due to less optimistic macroeconomic data.

Risk/Reward Ratings: Based on our analysis and assessment of the market's appeal to pharmaceutical companies in our Q314 Pharmaceutical Risk/Reward Ratings (RRRs), the Americas scores 49 out of 100, below the Western Europe region (67), Central and Eastern Europe (52), and Asia Pacific (5 2 ) , but above the Middle East and Africa (42) region. Of the seven Central American countries surveyed, at 40.9 Panama's RRR score ranks first, followed by Costa Rica (37.6), Guatemala (34.3), Honduras (34.2), Belize (32.4), El Salvador (32.0) and Nicaragua (29.8).

Key Trends And Developments

  • In April 2014, The Costa Rican social security administration (Caja Costarricense de Seguro Social, CCSS) reported that antineoplastic drugs and biologics had the highest revenue growth in the CCSS pharmaceutical procurements. Although the products were not purchased in large quantity, they have the highest costs. In 2013, a total of 9mn units of these drugs cost the fund over USD28mn. These products are not broadly available in pharmacies, as they are very expensive for general patients to purchase the full dose. Cefa Central Farmacéutica, Baxter Export Costa Rica, Pfizer,Novartis Pharma...

Table of Contents

BMI Industry View
7
SWOT
9
SWOT
9
Industry Forecast
10
Pharmaceutical Market Forecast
10
Table: Central America Minus Mexico Pharmaceutical Sales, Historic Data And Forecasts
11
Guatemala
11
Table: Guatemala Pharmaceutical Sales Forecasts
12
Costa Rica
12
Table: Costa Rica Pharmaceutical Sales Forecasts
13
El Salvador
13
Table: El Salvador Pharmaceutical Sales Forecasts
14
Honduras
14
Table: Honduras Pharmaceutical Sales Forecasts
15
Panama
15
Table: Panama Pharmaceutical Sales Forecasts
15
Nicaragua
16
Table: Nicaragua Pharmaceutical Sales Forecasts
16
Belize
17
Table: Belize Pharmaceutical Sales Forecasts
17
Healthcare Market Forecast
18
Table: Central America Minus Mexico Healthcare Expenditure Trends, Historical Data and Forecasts
19
Guatemala
19
Table: Guatemala Healthcare Expenditure Forecasts
19
Costa Rica
19
Table: Costa Rica Healthcare Expenditure Forecasts
20
El Salvador
20
Table: El Salvador Healthcare Expenditure Forecasts
22
Panama
22
Table: Panama Healthcare Expenditure Forecasts
23
Honduras
23
Table: Honduras Healthcare Expenditure Forecasts
24
Nicaragua
24
Table: Nicaragua Healthcare Expenditure Forecasts
24
Belize
25
Table: Belize Healthcare Expenditure Forecasts
25
Pharmaceutical Trade Forecast
26
Guatemala
27
Table: Guatemala Pharmaceutical Trade Data And Forecasts (USDmn)
28
Costa Rica
28
Table: Costa Rica Pharmaceutical Trade Data And Forecasts (USDmn)
28
El Salvador
29
Table: El Salvador Pharmaceutical Trade Data And Forecasts (USDmn)
29
Panama
29
Table: Panama Pharmaceutical Trade Data And Forecasts (USDmn)
30
Honduras
30
Table: Honduras Pharmaceutical Trade Data And Forecasts (USDmn)
30
Nicaragua
31
Table: Nicaragua Pharmaceutical Trade Data And Forecasts (USDmn)
31
Belize
31
Industry Risk Reward Ratings
32
Americas Risk/Reward Ratings
32
Central America Risk/Reward Ratings
38
Industry Trends And Developments
39
Regional Developments
39
Guatemala
41
Costa Rica
42
El Salvador
46
Panama
48
Honduras
48
Nicaragua
50
Belize
51
Epidemiology
52
Clinical Trials
53
Regulatory Development
56
Intellectual Property Regime
56
Costa Rica
57
El Salvador
58
Honduras
58
Nicaragua
59
Panama
59
Guatemala
59
Competitive Landscape
60
Company Profile
61
Ancalmo Internacional
61
Donovan Werke
63
Glossary
65
Methodology
67
Pharmaceutical Expenditure Forecast Model
67
Healthcare Expenditure Forecast Model
67
Notes On Methodology
68

The Central America Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Central America Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Panamanian, Guatemalan, Nicaraguan, Salvadoran, Costa Rican, Belizean, Honduran pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Panama, Guatemala, Nicaragua, El Salvador, Costa Rica, Belize, Honduras to test other views - a key input for successful budgeting and strategic business planning in the Panamanian, Guatemalan, Nicaraguan, Salvadoran, Costa Rican, Belizean, Honduran pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Panamanian, Guatemalan, Nicaraguan, Salvadoran, Costa Rican, Belizean, Honduran pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Panama, Guatemala, Nicaragua, El Salvador, Costa Rica, Belize, Honduras.
  • Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

Coverage

BMI Industry View & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc